Navigation Links
Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
Date:12/1/2009

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the waiting period has expired under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to Vanda's agreement, dated October 12, 2009, with Novartis Pharma AG, and that the agreement is now effective. Expiration of the waiting period, and the resulting effectiveness of the agreement, triggers an upfront payment to Vanda of $200 million.

Pursuant to the agreement, Novartis will have exclusive commercialization rights to Fanapt(TM) in the U.S. and Canada. Novartis will be responsible for the further clinical development activities in these territories, including the development and commercialization of a long-acting injectable (or depot) formulation of Fanapt(TM). Vanda will retain rights to commercialize Fanapt(TM) oral and depot formulations outside the U.S. and Canada, but Novartis has the option to enter into discussions with Vanda to co-commercialize Fanapt(TM) or receive sales royalties outside the U.S. and Canada.

About Vanda

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.

SOURCE Vanda Pharmaceuticals Inc.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
Breaking Medicine Technology:
(Date:7/20/2017)... , ... July 20, 2017 , ... The Dermatology Clinic ... Dr. Dunbar received his BS in Biology from LSU, graduating summa cum laude. He ... Class President. After his residency in St. Louis, Dr. Dunbar moved to New York ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Business Architecture ... of Knowledge (BIZBOK® Guide )v 6.0 is now available for member download. This ... Guild collaborative teams. , Non-members may download the Part 1 Introduction for ...
(Date:7/20/2017)... ... July 20, 2017 , ... LINET, an international leader in healthcare technology and ... the AVE 2 birthing bed. , Perfectly suitable for labor, delivery, recovery and postpartum; ... and efficiency to every phase of childbirth. The AVE 2 has many features that ...
(Date:7/20/2017)... Waco, TX (PRWEB) , ... July 19, 2017 , ... ... announce the availability of temporomandibular joint (TMJ) treatment and dental implants in ... the TRIOS® intraoral scanner and the T-Scan™ by Tekscan®, they can capture details in ...
(Date:7/20/2017)... ... 19, 2017 , ... Adolfson & Peterson Construction (AP) continues ... As a leader in healthcare construction, AP has successfully built several well-known medical ... Midwest with Josh now on board. , Josh brings over nine years ...
Breaking Medicine News(10 mins):